State of New Jersey Common Pension Fund D Sells 1,349 Shares of Twist Bioscience Co. (NASDAQ:TWST)

State of New Jersey Common Pension Fund D decreased its holdings in Twist Bioscience Co. (NASDAQ:TWST) by 2.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 45,102 shares of the company’s stock after selling 1,349 shares during the quarter. State of New Jersey Common Pension Fund D owned 0.08% of Twist Bioscience worth $2,038,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Swiss National Bank boosted its holdings in Twist Bioscience by 0.8% during the 1st quarter. Swiss National Bank now owns 114,000 shares of the company’s stock worth $3,911,000 after acquiring an additional 900 shares during the last quarter. Sei Investments Co. grew its position in Twist Bioscience by 32.7% in the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after purchasing an additional 55,124 shares in the last quarter. ProShare Advisors LLC increased its stake in Twist Bioscience by 10.2% in the 1st quarter. ProShare Advisors LLC now owns 14,444 shares of the company’s stock valued at $496,000 after buying an additional 1,336 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Twist Bioscience by 14.8% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 18,649 shares of the company’s stock worth $640,000 after buying an additional 2,410 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of Twist Bioscience in the 1st quarter worth approximately $242,000.

Insiders Place Their Bets

In other news, Director Robert Chess sold 3,600 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the sale, the director now directly owns 21,641 shares of the company’s stock, valued at approximately $1,022,753.66. This represents a 14.26 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the transaction, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. This represents a 1.15 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,118 shares of company stock worth $4,391,151 over the last 90 days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Trading Down 5.3 %

TWST opened at $36.89 on Friday. Twist Bioscience Co. has a 12 month low of $18.80 and a 12 month high of $60.90. The company has a market cap of $2.16 billion, a PE ratio of -9.66 and a beta of 1.78. The company has a 50 day moving average of $43.90 and a 200 day moving average of $46.02.

Analyst Ratings Changes

A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Leerink Partners boosted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.